Drug Combination on Exercise Performance at High Altitude
Information source: University of Montana
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Mountain Sickness
Intervention: ambrisentan and theophylline (Drug); placebo (Drug)
Phase: Phase 2/Phase 3
Status: Completed
Sponsored by: University of Montana
Summary
This study is being conducted to determine the effectiveness of using two FDA approved
medications in concert to reduce the likelihood of sickness due to low oxygen levels and to
reduce the decrement in physical performance at higher elevations. The investigators
hypothesize that this drug combination will reduce the symptoms of acute mountain sickness
and improve exercise performance at high altitude compared to placebo.
Clinical Details
Official title: Enhancing Physical Performance and Mitigating Acute Mountain Sickness Via Pharmaceutical Intervention While at Altitude
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)
Primary outcome: Time (minutes) to complete 2 miles on a treadmill
Secondary outcome: Time (minutes) to complete 2 miles on a treadmill
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- healthy males
Exclusion Criteria:
- VO2max below 45ml/kg/min
- currently taking any medication
Locations and Contacts
Montana Center for Work Physiology and Exercise Metabolism, Missoula, Montana 59812, United States
Additional Information
Starting date: August 2013
Last updated: February 26, 2014
|